CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML
The purpose of the study is to determine the safety of combining the drugs gemtuzumab ozogamicin (GO) with CPX-351 in order to treat the disease, as well as to find the maximum tolerated dose level and recommended Phase 2 dose level of GO with a fixed dose of CPX-351.
Acute Myeloid Leukemia
DRUG: Vyxeos|DRUG: Gemtuzumab Ozogamicin
Maximum Tolerated Dose (MTD), Dose escalation will determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Vyxeos plus Gemtuzumab Ozogamicin. The MTD is the highest dose of the combination therapy that dose not cause unacceptable side effects., Up to 18 Months
Rate of Complete Remission, Rate of complete remission (CR) and complete remission with incomplete blood count recovery (CRi). The definition of CR and CRi is based on the European LeukemiaNet 2017 Response Criteria for AML., Up to 18 Months|Measurable Residual Disease, Rate of measurable residual disease via RT-PCR for core binding factor leukemia as well as NPM1 mutated AML, Up to 18 Months|Overall Survival, Overall survival is defined as the duration of time from start of treatment to the time of death from any cause or date of last contact., Up to 5 years|Relapse Free Survival (RFS), RFS is defined as time interval between achievement of CR to time of relapse, Up to 18 Months
The purpose of the study is to determine the safety of combining the drugs gemtuzumab ozogamicin (GO) with CPX-351 in order to treat the disease, as well as to find the maximum tolerated dose level and recommended Phase 2 dose level of GO with a fixed dose of CPX-351.